Navigation Links
Motor nerve targeting to limb muscles is controlled by ephrin proteins
Date:12/24/2008

f limb nerve development, this team of scientists contributes further to the development of new strategies for treatment of patients with a diseased and damaged nervous system. That is because knowing how nerves form is crucial in designing therapies that aim to rebuild damaged or diseased nerves.

"The study of the ephrin proteins should help us understand diseases such as autism, schizophrenia as well as a number of neurological disorders," says Dr. Rmi Quirion, a scientific director at the Canadian Institutes of Health Research (CIHR). "We are proud to support this important study and hope it will help to improve the lives of people with these health problems."


'/>"/>

Contact: Dr. Artur Kania
Artur.Kania@ircm.qc.ca
514-987-5526
Institut de recherches cliniques de Montreal
Source:Eurekalert

Page: 1 2

Related biology news :

1. Silicon Valley Technology Leaders LaserCard Corporation and Tesla Motors Sign LaserPass Secure Access Deal
2. Motor neuron disease and toxic substances: Possible link?
3. Motorola Biometric Identification System Selected by West Virginia State Police
4. Motorola Biometric Identification System Selected by West Virginia State Police
5. Motorola Introduces Mobile Biometric Identification for Handheld Computers
6. SAFRAN to Acquire Motorolas Biometrics Business
7. Specific brain protein required for nerve cell connections to form and function
8. Targeting nerve growth factor may cure liver cancer
9. West Nile virus spread through nerve cells linked to serious complication
10. Team of scientists develops non-invasive method to track nerve-cell development in live human brain
11. Salk scientists identify key nerve navigation pathway
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) a ... the recent success of the Wocket™ smart wallet at CES 2015 in ... was named as one of the "11 Hot Products at CES" in ... At CES So Far" by Newseveryday.com and "The top 10 gadgets from ...
(Date:1/22/2015)... , January 22, 2015 , ... year  The European Patent Office to present a video ... British nominations to be featured: Christofer Toumazou and ... former finalists and winners of the Award   Starting ...
(Date:1/22/2015)... has launched its new NXG series of time clocks with ... higher standard for collecting attendance and labor data and complements ... touch screen interface and seamless connection to cloud-based iSolved, the ... for the small to mid-size employer. The G2 ...
Breaking Biology News(10 mins):CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3Infinisource's NXG series sets new time clock standard 2
... researchers have identified the neurocircuit that controls the brain's ... be possible to understand psychiatric disorders, such as anxiety ... brain. , They accomplished this using an adapted version ... that enables analysis of function in the brain. , ...
... the January/February 2007 issue of Physiological and Biochemical Zoology, ... may respond to water diversion and climate change. Endangered ... spawn, and a lake in Western China, where they ... and becoming increasingly more saline--leading to surprising adjustments to ...
... blood oxygen levels of a baby during labor--expected to ... benefit, report researchers in a National Institutes of Health ... saturation monitoring, was designed for use along with electronic ... measure changes in fetal oxygen levels. Designers of ...
Cached Biology News:Emotional control circuit of brain's fear response discovered 2Emotional control circuit of brain's fear response discovered 3Climate change has surprising effect on endangered naked carp 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 2Technology for monitoring fetal oxygen during labor offers no apparent benefit 3
(Date:2/27/2015)... Markets ( http://www.researchandmarkets.com/research/p2ddnr/global_market ) has announced the addition ... to their offering. , Global Market Report ... Trypsin globally and regionally ( Europe , ... Latin America etc.). It captures Trypsin ... report focuses on three primary areas; manufacture methods & technology ...
(Date:2/27/2015)... Feb. 27, 2015  Pfenex Inc. (NYSE MKT: PFNX), ... biosimilar therapeutics, today announced that it will be presenting ... on March 2 nd at 3pm PST. Patrick Lucy, ... panel discussing the current state of the biosimilar industry ... For more information on CALBIO 2015 ...
(Date:2/27/2015)... --  PureTech , a science and technology R&D company ... technologies in the healthcare sector, announced today the appointment ... of the Board of Directors of Sanofi, to its ... a pleasure to know Chris for many years and ... together more closely now," said Dr. Robert Langer ...
(Date:2/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... that develops and commercializes proprietary technologies and products for ... results for the fiscal first quarter ended December  31, ... Canadian dollars (CAD), unless otherwise stated. ... business from our existing customers and add to our ...
Breaking Biology Technology:Global Market Report of Trypsin 2014-2018 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4SQI Diagnostics Reports First Quarter Financial Results 2SQI Diagnostics Reports First Quarter Financial Results 3SQI Diagnostics Reports First Quarter Financial Results 4SQI Diagnostics Reports First Quarter Financial Results 5SQI Diagnostics Reports First Quarter Financial Results 6
... Trial in Medullary Thyroid Cancer Planned to Initiate ... 16 ,Exelixis, Inc. (Nasdaq: EXEL ) announced ... Drug Administration (FDA) have reached agreement on the ... anticancer compound targeting,MET, RET, and VEGFR2, via the ...
... Thermage Inc. To, Drive Coapt,s Growth In ... June 13 Coapt Systems, Inc.,developer of bioabsorbable implants ... and sports medicine markets, announced today the,appointment of Laureen ... as a member of the company,s Board of Directors. ...
... landmark IRIS trial, which established Gleevec as standard ... of care, - Study did not ... molecular responses with 800 vs. 400 ... optimize treatment benefit for individual ...
Cached Biology Technology:Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 2Coapt Systems New CEO, Laureen DeBuono, to Fuel Company's Growth and Product Innovation 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 2Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 3Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 4Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 5Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 6Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 7Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 8Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 9Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 10Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 11Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 12Video: Higher Initial Dose of Gleevec Achieved Better Early Responses than Standard Dose for Patients with Chronic Myeloid Leukemia 13
Request Info...
Mouse Galectin-1 Affinity Purified Polyclonal Ab...
EDG-1CT (endothelial cell differentiation gene-1, C terminal)...
Mouse monoclonal [MLM544] to cardiac Myosin light chain 1 ( Abpromise for all tested applications). entrezGeneID: 4634 SwissProtID: P08590...
Biology Products: